Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Study raises important questions about the use of drugs that promote or prevent angiogenesis

Dartmouth Medical School cardiology researchers have discovered a new mechanism for what drives the growth of muscle tissue in the lining of injured heart vessels that can eventually lead to blockage.

11 Oct 2004

Researchers discover mechanism that may help to explain how angiogenesis inhibitors work on normal, blood vessel-forming endothelial cells

Northwestern University researchers have discovered a mechanism that may help to explain how angiogenesis inhibitors work on normal, blood vessel-forming endothelial cells, but not on insidious, aggressive melanoma cells that masquerade as endothelial-like cells by forming their own vascular networks, called "vasculogenic mimicry."

8 Oct 2004

Researchers discover new mechanism responsible for blood vessel tumors that cause facial deformities

Researchers have discovered a new mechanism responsible for the growth of blood vessel tumors that can cause facial deformities in infants and young children, paving the way for an antibody-based treatment to remove cells that fuel the tumors’ growth.

5 Oct 2004

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

A revolutionary approach to angiogenesis could make cancer treatment more effective at killing tumours

Dr. Olivier Feron and his team from the University of Louvain Medical School in Brussels have turned the whole concept of targeting tumour blood vessels on its head. Instead of the conventional approach of trying to starve tumour cells of the blood supply they need to grow, they are doing the opposite – opening up the tumour blood supply to allow better access for cancer drugs and more effective radiotherapy.

30 Sep 2004

HER-2 cell surface receptors tun on genes associated with carcinogenesis

Researchers at The University of Texas M. D. Anderson Cancer Center now have evidence that receptors found on tumors that were believed to function only on the surface of cells can actually switch on genes inside a cell's nucleus, thus promoting cancer development in two distinct ways.

21 Sep 2004

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development.

20 Sep 2004

Drug combo may have a greater impact on cancer development

Cancer researchers have long suggested that new targeted drugs may work best when paired with other therapies. In a new study published today in Cancer Research, scientists have taken some of the first steps to demonstrate this synergy in mouse and cell line models.

16 Sep 2004

Researchers are making inroads to understanding what makes brain tumors so hard to treat

When he's not in the operating room performing surgery, Donald M. O'Rourke, M.D., Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine is fighting brain tumors from the research laboratory bench.

16 Sep 2004

Dual-action compound shows promise in killing prostate cancer cells

Ohio State University researchers are working on developing a multi-purpose cancer drug that might one day scale back the number of medications some cancer patients need to take.

22 Aug 2004

Novel pharmacological target for cannabinoid-based therapies

Cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to brain tumors by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).

15 Aug 2004

Genentech announces FDA approval of Avastin manufacturing

Genentech has announced that the U.S. Food and Drug Administration approved the supplemental Biologics License Application (sBLA) for the manufacturing of Avastin™ (bevacizumab) bulk drug substance at the company's facility in Vacaville, California.

11 Aug 2004

Bionomics BNO69 angiogenesis gene discovery published

Bionomics has announced that research conducted by Bionomics and its collaborators at the Hanson Centre of the Institute of Medical and Veterinary Science ("IMVS") in Adelaide, Australia, relating to Bionomics' proprietary angiogenesis drug target BNO69, has been published in the high ranking scientific journal Proceedings of the National Academy of Sciences USA (PNAS).

10 Aug 2004

One-third of U.S. adults use some form of alternative medicine

More than one-third of U.S. adults use some form of alternative medicine such as herbal supplements and other therapies, showed in a nationwide survey by NIH's National Center for Complementary and Alternative Medicine published in May 2004.

2 Aug 2004

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

An international team of scientists has identified an important molecular link involved in the spread – or metastasis – of melanoma to other organs such as the lungs.

15 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Treatment with a new dual cell cycle and angiogenesis pathway inhibitor blocks VEGF-induced vascular permeability, inhibits tumour angiogenesis and induces apoptosis in human tumour models

7 Jul 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Chemicals that inhibit the development of new blood vessels could prove to be a new way of treating endometriosis

Chemicals that inhibit the development of new blood vessels could prove to be a new way of treating endometriosis, according to research from The Netherlands and the USA presented today (Monday 28 June) at the 20th annual meeting of the European Society of Human Reproduction and Embryology.

28 Jun 2004

Potential new strategy for blocking tumor growth

Targeting a master molecule that helps cancer cells survive when blood oxygen levels are low may offer a potentially powerful strategy for blocking tumor growth, say researchers at The University of Texas M. D. Anderson Cancer Center.

16 Jun 2004